PfSPZ-GA1 / Sanaria - LARVOL DELTA

Creation and preclinical evaluation of genetically attenuated malaria parasites arresting growth late in the liver. (PubMed, NPJ Vaccines) - "A recent clinical trial with a WSp vaccine comprising genetically attenuated parasites (GAP) which arrest growth early in the liver (PfSPZ-GA1), showed that GAPs can be safely administered to humans and immunogenicity is comparable to radiation-attenuated PfSPZ Vaccine...These features of PfΔmei2 make it a promising vaccine candidate, supporting further clinical evaluation. PfΔmei2 (GA2) has passed regulatory approval for safety and efficacy testing in humans based on the findings reported in this study."

Journal • Preclinical • Infectious Disease • Malaria